Study of Irinotecan & Capecitabine in Metastatic Colorectal Cancer
- Sponsor
- National Cancer Center, Korea
- Study ID
- NCT00506168
- Phase
- PHASE2
- Status
- Terminated
Conditions
- Colorectal Neoplasms
- Drug Therapy, Combination
- Secondary
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Irinotecan, Capecitabine — DRUG
Study Details
This study is to evaluate the efficacy and safety of combination chemotherapy with irinotecan and capecitabine in previously untreated metastatic colorectal cancer.
Key Dates
- Start date
- Nov 30, 2001
- Status verified
- Jul 2007
- Completion
- Jul 31, 2007
Study Design
- Enrollment
- 37 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Maximal response rate and toxicities [ Time Frame: During treatment ]
Related Studies
- Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal CancerPHASE3 · Recruiting · Surgimab · Duarte, California
- Metarrestin (ML-246) in Subjects With Metastatic Solid TumorsPHASE1 · Recruiting · National Cancer Institute (NCI) · Fairway, Kansas
- Changes in Reproductive and Sexual Health in People With Early Onset Colorectal CancerRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey